Zacks: Brokerages Expect Motus GI Holdings, Inc. (NASDAQ:MOTS) Will Post Quarterly Sales of $240,000.00

Brokerages predict that Motus GI Holdings, Inc. (NASDAQ:MOTSGet Rating) will post $240,000.00 in sales for the current quarter, according to Zacks. Three analysts have provided estimates for Motus GI’s earnings, with the lowest sales estimate coming in at $100,000.00 and the highest estimate coming in at $400,000.00. Motus GI posted sales of $100,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 140%. The firm is expected to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Motus GI will report full year sales of $1.29 million for the current financial year, with estimates ranging from $610,000.00 to $1.90 million. For the next year, analysts anticipate that the company will report sales of $6.39 million, with estimates ranging from $2.98 million to $9.80 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Motus GI.

Motus GI (NASDAQ:MOTSGet Rating) last released its earnings results on Tuesday, March 29th. The company reported ($0.10) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.10). Motus GI had a negative net margin of 5,331.94% and a negative return on equity of 152.78%. The firm had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.14 million. During the same period last year, the business earned ($0.12) earnings per share.

MOTS has been the subject of several recent research reports. Alliance Global Partners lowered their target price on shares of Motus GI from $1.75 to $1.40 in a report on Wednesday, January 26th. HC Wainwright lowered their target price on shares of Motus GI from $2.00 to $1.50 and set a “na” rating for the company in a report on Monday. Finally, Colliers Securities reiterated a “buy” rating on shares of Motus GI in a report on Tuesday, March 22nd.

A number of hedge funds and other institutional investors have recently made changes to their positions in MOTS. Morgan Stanley grew its position in Motus GI by 41.7% in the 2nd quarter. Morgan Stanley now owns 51,000 shares of the company’s stock worth $53,000 after purchasing an additional 15,000 shares during the period. Citadel Advisors LLC grew its position in Motus GI by 276.3% in the 2nd quarter. Citadel Advisors LLC now owns 46,447 shares of the company’s stock worth $48,000 after purchasing an additional 34,103 shares during the period. BlackRock Inc. grew its position in Motus GI by 13.5% in the 3rd quarter. BlackRock Inc. now owns 202,808 shares of the company’s stock worth $139,000 after purchasing an additional 24,100 shares during the period. Millennium Management LLC grew its position in Motus GI by 20.4% in the 3rd quarter. Millennium Management LLC now owns 118,652 shares of the company’s stock worth $82,000 after purchasing an additional 20,110 shares during the period. Finally, LPL Financial LLC bought a new stake in Motus GI in the 4th quarter worth approximately $25,000. Institutional investors own 7.48% of the company’s stock.

Shares of MOTS stock traded up $0.02 during trading hours on Tuesday, hitting $0.26. 144,717 shares of the company’s stock traded hands, compared to its average volume of 1,141,885. The stock’s fifty day simple moving average is $0.31 and its two-hundred day simple moving average is $0.42. Motus GI has a 12-month low of $0.23 and a 12-month high of $1.22. The stock has a market cap of $14.05 million, a price-to-earnings ratio of -0.66 and a beta of 2.40. The company has a quick ratio of 6.42, a current ratio of 6.63 and a debt-to-equity ratio of 1.20.

Motus GI Company Profile (Get Rating)

Motus GI Holdings, Inc, a medical technology company, develops Pure-Vu system, a medical device to facilitate the cleaning of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedure. The company was incorporated in 2016 and is based in Fort Lauderdale, Florida.

Featured Stories

Get a free copy of the Zacks research report on Motus GI (MOTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Motus GI (NASDAQ:MOTS)

Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.